Safety of Moderna’s mRNA RSV Vaccine for Infants Heads Dec 12 VRBPAC Meeting Agenda
Moderna paused clinical research on the pediatric shot indefinitely in September after reports in July of severe adverse reactions in infants aged 5 to 8 months.
Atogepant Improves QoL, Function in Adults with Chronic, Episodic, Treatment-Resistant Migraine
An analysis of patient reported outcome measures from 3 pivotal phase 3 RCTs of atogepant 60 mg demonstrates efficacy across functional domains as well as for migraine prevention.
10 More Can't Miss Doctor Gifts Worth Giving...or Having
An MDF stethoscope with leopard print tubing? A digital highlighter/scanner that translates and talks back? Check out these and 8 more uncommon gifts for health care professionals.
Americans Rate US Health Care at All-Time Low: A Gallup Survey Snapshot
Americans' rating of the quality of health care available in the US has hit its lowest in 24 years, according to a new Gallup survey; here's what they think.
10 Questions on Holiday Spirits
How does alcohol figure in to American holiday celebrations? We checked with Alcohol.org for this quiz. Are answers what you expect?
Dupilumab Effective in Young Children with Atopic Dermatitis, Comorbid T2 Inflammatory Disease
Dupilumab significantly reduced signs and symptoms of AD in children aged 6 months to 5 years with concomitant asthma, allergic rhinitis, and food allergy.
Fremanezumab Safe and Effective for Prevention of Episodic Migraine in Children: Phase 3 Data Announced
The CGRP inhibitor fremanezumab reduced both monthly migraine and monthly headache days among children aged 6 to 17 years with a favorable safety profile.
Tirzepatide Bests Semaglutide for Weight Loss by 47% in Head-to-Head Trial
"Twincretin" tirzepatide-treated participants in SURMOUNT-5 lost a mean 50 lbs vs an average loss of 33 lbs for those treated with semaglutide.
NDA Submission for Anaphylm (Epinephrine) Sublingual Film on Track for Q1 2025, Company Says
Aquestive Therapeutics announced positive feedback from the FDA this week that keeps NDA planning for the novel epinephrine product on solid ground.
10 Can't Miss Doctor Gifts Worth Giving in 2024
Holiday health care gift-giving season is here and we've done some window shopping for our primary care readers. Take a breath and scroll through our top 10 suggestions for 2024.
Online Misinformation on UTIs, ASB is Common and Dangerous: New Research
At least 1 accurate UTI symptom was found on most of the 331 websites reviewed, but nearly all (80%) included at least 1 inaccurate or misleading one.
More than Half of US Adults May Be Eligible for Semaglutide Therapy, Accordng to New Estimates
Millions of US adults could benefit from semaglutide treatment for diabetes, obesity, and/or CV disease but insurance isn't guaranteed and the drug is costly.
Antivirals for Influenza Underutilized Among Vulnerable Children, Adolescents
Analysis of surveillance data revealed a decline in use of antiviral medications for children hospitalized with influenza and prevalent underprescribing in outpatient settings.
For Agitation in Alzheimer Disease, a Novel, Oral NMDA Receptor Antagonist Could be the Next Targeted Treatment
Geriatric psychiatrist and neurocognitive researcher George Grossberg, MD, highlights the mechanism of action for the new dextromethorphan/bupropion combination.
Exercise of Any Level Linked to Reduced All-Cause Mortality in Individuals with Dementia
Physical activity of any level before and after a diagnosis of dementia was associated with at least a 20% lower risk for all-cause mortality across dementia subtypes.
Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in High-Risk Adults: Phase 2 Data
Lp(a) is a genetically-driven and independent risk factor for CVD with no approved treatments. Lilly is advancing muvalaplin and has some good competition.
Awareness of Lung Cancer Screening Extremely Low Among Those at Highest Risk in the US: New Data
Among current smokers, 71% had never spoken a clinician about screening and among those who had quit, 75% had never had a conversation.
Intensive SBP Reduction Below 120 mm Hg Reduces MACE in Adults with Type 2 Diabetes
AHA 2024. Findings from the BPROAD trial help fill a gap left by similar studies on the ideal target SBP for adults with type 2 diabetes, said study authors.
European Medicines Agency Reverses Opinion on Lecanemab for Alzheimer Disease But Limits Eligible Population
The EMA recommendation excludes from treatment adults who are homozygous for the ApoE ε4 gene, a decision that the US Alzheimer's Association does not support, said the president/CEO.
Risk Factors for Type 1 Diabetes: A Snapshot for Primary Care
About 40% of people who have T1D are not aware of it until they experience an extreme health event; screening in primary care can help reduce the risk, support families.
World Diabetes Day 2024: Diabetes Facts & Stats & a Call to Act
A quick review of the scope of diabetes in the US and of the gaps in equitable access to care supports the annual call to action from the International Diabetes Federation.
Obstructive Sleep Apnea Linked to Increased Risk for Dementia, Particularly in Women
Michigan Medicine researchers found that at all age levels, women with known/suspected OSA were more likely than men to be diagnosed with dementia.
11 Things You Should NOT Say to Patients: How to Replace the "Never-Words"
The 11 words and phrases, among others, are often automatic responses from clinicians in highly emotional settings of severe illness. Find 11 alternatives, here.
Death Rates from Obesity-Related Heart Disease Soared Nearly 200% Between 1990 and 2020, Researchers Report
AHA 2024. "...we did not anticipate this magnitude of increase in mortality," researchers said. They were also surprised by the population groups most affected.
Among Stroke Survivors, GLP-1RAs, SGLT2is May Reduce Risk of Future MI, Recurrent Stroke
AHA 2024. Study authors reported a 74% lower risk of death and an 84% lower risk of MI among participants taking either a GLP-1RA or an SGLT2i.
FDA May End Use of Oral Phenylephrine as Nasal Decongestant Ingredient in OTC Products
A decision on ending use of oral phenylephrine as a nasal decongestant in OTC products will be made following public comment on FDA's proposed order.
8 Antiobesity Therapies to Watch Closely
Dual and triple incretin agonists continue to lead the new therapies in the antiobesity pipeline. Here is an at-a-glance update of their progress toward approval.
Data Published on Sotagliflozin Used to Reduce HbA1c in Adults with Type 1 Diabetes and Kidney Disease
The data, published in JASN, were presented last week to an FDA advisory committee considering recommending sotagliflozin as an adjunct to insulin in adults with T1D and CKD.
When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.